A Prospective, Single center, Single-Arm Clinical Study of 13-20 study participants who are seeking a procedure to reduce the appearance of the peri-orbital wrinkles. Each study participant will receive up to four (4) treatments with the Tixel in a monthly interval. Follow-up will occur 1 month and 3 months following last treatment.

A Prospective, Single center, Single-Arm Clinical Study of 13-20 participants who are seeking a procedure to reduce the appearance of the peri-orbital wrinkles, and meet study eligibility criteria, and have provided informed consent will be enrolled in the study. Each study participate will receive up to 4 treatments with Tixel in monthly interval. Follow-up will occur at 1 month and 3 months following the last visit.

The clinic visits will be as follow:

1. Base line (1st tx)
2. Phone-call visit (3 days after the first treatment)
3. 4 week (2nd tx)
4. 8 week (3rd tx)
5. 12 week (4th tx)
6. 4 weeks after the last treatment (1st Follow-up)
7. 12 weeks after the last treatment (2nd follow-up = 3 months follow-up, primary endpoint and the study completion visit)

Primary Safety Endpoint is the evaluation of related adverse events up to the 3-month visit after treatment.

Inclusion Criteria:

1. Male or female 35-75 years old diagnosed with clinically evident fine (mild) to moderate depth periorbital wrinkles.
2. Willingness and ability to comply with all required study activities including returning for follow-up visits and protocol requirements.
3. The subject is able to provide written informed consent and perform the study's activities according to HIPAA guidelines.
4. Fitzpatrick wrinkle score of 3-7 in the peri-orbital areas per the treating investigator.
5. Stable body weight during the study period.
6. Skin Type I - V as per Fitzpatrick Skin Scale

Exclusion Criteria:

1. Past treatment with Tixel device.

2. The subject may not undergo treatment by the Tixel device according to the device's contra-indications for use, as defined in the User Manual and in the Instructions for Use and by any other labeling of the device.

3. Subjects who, in the investigator's opinion, have a history of poor cooperation, noncompliance with medical treatment, or unreliability.

4. Female subjects who are pregnant, or planning to become pregnant, or have given birth less than 3 months ago or are lactating.

5. Subjects with significant exposure to critical amounts of ultraviolet light (Suntan).

6. Subjects who have had the following treatments:

   1. a cosmetic procedure to improve periorbital rhytides within 6 months.
   2. Injectable filler in temples and in the upper face area to be treated within 12 months of investigation.

7. Any subject who have visible scars or other visible changes over the treated areas that may affect evaluation of response and/or quality of photography.

8. Subjects with any type of active cut, wound, inflammation, lesion (benign, premalignant or malignant) or active bacterial, viral, fungal, or herpetic infection on the skin on the designated treatment sites or in close proximity to it.

9. Existing or history of the following (when discussing skin conditions, refers only to the periorbital sites):

   1. skin malignancy, or any diagnosis of suspected malignancy
   2. Collagen or vascular or bleeding disease
   3. Immunosuppression or autoimmune disease
   4. History of persistent beyond 2 years post inflammatory hyperpigmentation.
   5. Active Acne Vulgaris, HSV-1, or any existing skin condition/disease that in the investigator's opinion would interfere with the evaluation of the safety of the study treatment and evaluation.
   6. Any skin condition which can induce bullous lesions, urticaria, or demonstrate a Koebner phenomenon (psoriasis, lichen planus, etc.).
   7. Any disease that inhibits pain sensation
   8. History of keloid formation.
   9. Conditions affecting healing rate (i.e. diabetes mellitus I or II, vascular condition, etc.)
   10. neuromuscular disorders

10. Subjects who have used, within 30 days, any medication over the periorbital area that can cause dermal hypersensitivity or affect skin characteristics over the treated area (i.e. topically applied retinoids, hydroquinone, Chemical peel of any strength: glycolic acid, lactic acid, salicylic acid)

11. Subjects who have used, systemic treatment which may induce dyspigmentation within 12 months, such as amiodarone, clofazinmine, minocycline or chloroquine.

12. Subjects currently taking or have taken an oral retinoid in the past 6 months;Subjects currently taking long-term oral steroid treatment.

13. Concurrent therapy that, in the principal investigator's opinion, would interfere with the evaluation of the safety or efficacy of the study treatment.

14. Subjects who anticipate the need for major surgery or overnight hospitalization during the study that can affect the study schedule or treatment evaluation.

15. Enrollment in any active study involving the use of investigational devices or drugs which would impact the periorbital response.

16. Any other cause per the principal investigator's discretion.

Undecided

Blinded assessed of the improvement would be done between Last FU images and baseline, following randomization of the images.